Guardant Health Outcomes Model Confirms the Public Health Importance of Enhanced Colorectal Cancer Screening Outcomes with High Adherence Strategies
Research Study Accepted for Publication Demonstrates Efficacy of Blood-Based Tests for CRC Screening
The CAN-SCREEN model addresses the significant limitations of existing models, which often assume absolute adherence to screening protocols. These assumptions fail to accurately predict population-level health outcomes, overlooking the real-world challenges and preferences of patients.
A key benefit of Guardant Health’s blood-based screening test, Shield™, is the potential to reduce CRC-related mortality due to its high adherence. This non-invasive screening modality is designed to maximize patient adherence, offering a more accessible and preferable option than traditional methods. By integrating this blood-based test into existing screening programs, the CAN-SCREEN model predicts a significant reduction in CRC-related deaths, particularly among previously unscreened populations. The model also predicts that patients screened with blood-based testing gained more life years, compared to those screened with FIT or mtsDNA.
“At Guardant Health, our mission is to enhance cancer detection and improve patient outcomes through innovative solutions,” said AmirAli Talasaz, Co-CEO of
About
References
Forbes, S. P., Yay Donderici, E., Zhang, N., et al. (2024). Population health outcomes of blood-based screening for colorectal cancer in comparison to current screening modalities: insights from a discrete-event simulation model incorporating longitudinal adherence.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240801502329/en/
Investor Contact:
investors@guardanthealth.com
Media Contact:
press@guardanthealth.com
Source: